Novel Avenues of Drug Discovery and Biomarkers for Diabetes Mellitus
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Globally, developed nations spend a significant amount of their resources on health care initiatives that poorly translate into increased population life expectancy. As an example, the United States devotes 16% of its gross domestic product to health care, the highest level in the world, but falls behind other nations that enjoy greater individual life expectancy. These observations point to the need for pioneering avenues of drug discovery to increase life span with controlled costs. In particular, innovative drug development for metabolic disorders such as diabetes mellitus becomes increasingly critical given that the number of diabetic people will increase exponentially over the next 20 years. This article discusses the elucidation and targeting of novel cellular pathways that are intimately tied to oxidative stress in diabetes mellitus for new treatment strategies. Pathways that involve wingless, β-nicotinamide adenine dinucleotide (NAD(+)) precursors, and cytokines govern complex biological pathways that determine both cell survival and longevity during diabetes mellitus and its complications. Furthermore, the role of these entities as biomarkers for disease can further enhance their utility irrespective of their treatment potential. Greater understanding of the intricacies of these unique cellular mechanisms will shape future drug discovery for diabetes mellitus to provide focused clinical care with limited or absent long-term complications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dysfunction of Mitochondria in Human Skeletal Muscle in Type 2 Diabetes
Kelley, D. E., He, J., Menshikova, E. V., & Ritov, V. B. (2002) · Diabetes · doi:10.2337/diabetes.51.10.2944 · Cited by 2,321 · cited 1×
“In patients with type 2 DM, skeletal muscle mitochondria have been described to be smaller than those in control subjects.(182) A decrease in the levels of mitochondrial proteins Figure 1.”
BackgroundVariant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes
Grant, S. F. A., Thorleifsson, G., Reynisdottir, I., Benediktsson, R., Manolescu, A., Sainz, J., Helgason, A., Stefansson, H., Emilsson, V., Helgadottir, A., et al. (2006) · Nature Genetics · doi:10.1038/ng1732 · Cited by 2,287
Diabetes mellitus and the risk of dementia: The Rotterdam Study
Ott, A., Stolk, R. P., van Harskamp, F., Pols, H. A. P., Hofman, A., & Breteler, M. M. B. (1999) · Neurology · doi:10.1212/wnl.53.9.1937 · Cited by 2,175
Diabetes in Asia: Epidemiology, Risk Factors, and Pathophysiology
Chan, J. C. N., Malik, V., Jia, W., Kadowaki, T., Yajnik, C. S., Yoon, K.-H., & Hu, F. B. (2009) · JAMA · doi:10.1001/jama.2009.726 · Cited by 1,997
Steen, E., Terry, B. M., J. Rivera, E., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7107 · Cited by 1,703 · cited 2×
“130 • J Clin Pharmacol 2011;51:128-152 studies have described the reduced expression of genes encoding insulin in Alzheimer’s patients that suggests a potential link between DM and the development of Alzheimer’s disease.(43) Alzheimer’s disease can be the result of a number of etiologies,(44,45) such as changes in cer…”
BackgroundPathophysiologic Implications of Membrane Phospholipid Asymmetry in Blood Cells
Zwaal, R. F. A., & Schroit, A. J. (1997) · Blood · doi:10.1182/blood.v89.4.1121 · Cited by 1,340
A genome-wide search for human type 1 diabetes susceptibility genes
Davies, J. L., Kawaguchi, Y., Bennett, S. T., Copeman, J. B., Cordell, H. J., Pritchard, L. E., Reed, P. W., Gough, S. C. L., Jenkins, S. C., Palmer, S. M., et al. (1994) · Nature · doi:10.1038/371130a0 · Cited by 1,276 · cited 1×
“Prior work demonstrates that multiple loci with possible epistatic interactions among other loci may be responsible for genetic transmission.(19,20) Several environmental factors may have a role in type 1 DM; investigations have suggested that type 1 DM in monozygotic twins can occur with a cumulative risk of 70% from…”
BackgroundBitterman, K. J., Anderson, R. M., Cohen, H. Y., Latorre-Esteves, M., & Sinclair, D. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205670200 · Cited by 1,002 · cited 1×
“Physiological concentrations of nicotinamide noncompetitively inhibit Sir2, suggesting that nicotinamide is a physiologically relevant regulator of Sir2 enzymes.(356) Interestingly, nicotinamidase expression, which reduces nicotinamide concentrations, prevents both apoptotic late DNA degradation and early PS exposure…”
BackgroundIncidence of diabetes in youth in the United States
SEARCH for Diabetes in Youth Study Group*, T. W. G. F. T. (2007) · JAMA · doi:10.1001/jama.297.24.2716 · Cited by 991 · cited 1×
“The incidence of impaired glucose tolerance in the young raises further concerns.(6) Individuals with impaired glucose tolerance have a greater than twice the risk for the development of diabetic complications than individuals with normal glucose tolerance.”
BackgroundSandri, M., Lin, J., Handschin, C., Yang, W., Arany, Z. P., Lecker, S. H., Goldberg, A. L., & Spiegelman, B. M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607795103 · Cited by 974
De Felice, F. G., Velasco, P. T., Lambert, M. P., Viola, K., Fernandez, S. J., Ferreira, S. T., & Klein, W. L. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m607483200 · Cited by 882 · cited 1×
“At the cellular level, ROS are oxygen free radicals and other chemical entities that can lead to cell injury if left unchecked.(49,88,89) Oxidative stress can result in hepatic injury,(90,91) pancreatitis,(92) impaired cognition,(93,94) neuronal injury,(44,49,95-99) Parkinson’s disease,(100-103) complications of epile…”
BackgroundDiabetes and mortality following acute coronary syndromes
Donahoe, S. M., Stewart, G. C., McCabe, C. H., Mohanavelu, S., Murphy, S. A., Cannon, C. P., & Antman, E. M. (2007) · JAMA · doi:10.1001/jama.298.7.765 · Cited by 716 · cited 1×
“Patients with DM can develop multiple complications that include immune dysfunction,(26) sarcopenia,(27) depression,(28) hepatic dysfunction,(29) renal disease,(30) anemia and hematological disease,(31-33) neurodegenerative disorders,(8,34,35) and cardiovascular disease.(8,36) Interestingly, patients with DM are at ri…”
BackgroundNewsholme, P., Haber, E. P., Hirabara, S. M., Rebelato, E. L. O., Procopio, J., Morgan, D., Oliveira‐Emilio, H. C., Carpinelli, A. R., & Curi, R. (2007) · The Journal of Physiology · doi:10.1113/jphysiol.2007.135871 · Cited by 684
Di Lisa, F., Menabò, R., Canton, M., Barile, M., & Bernardi, P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m006825200 · Cited by 678
Chong, Z. Z., Li, F., & Maiese, K. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.02.004 · Cited by 536 · cited 2×
“ROS exposure can result in the opening of the mitochondrial membrane permeability transition pore,(145,179-181) reduce mitochondrial β-nicotinamide adenine dinucleotide (NAD) stores, and result in apoptotic cell injury.(44) Free fatty acids also can lead to ROS release, mitochondrial DNA damage, and impaired pancreati…”
BackgroundSelf-citationOrchard, T. J., Olson, J. C., Erbey, J. R., Williams, K., Forrest, K. Y.-Z., Smithline Kinder, L., Ellis, D., & Becker, D. J. (2003) · Diabetes Care · doi:10.2337/diacare.26.5.1374 · Cited by 492 · cited 1×
“Other variables reported in patients with type 1 DM include the presence of insulin resistance that is usually characteristic of type 2 DM and can lead to neurological and vascular disease.(16,17) Interestingly, there is a converse overlap with type 1 and type 2 DM, because almost 10% of type 2 DM patients may have el…”
BackgroundIdelson, M., Alper, R., Obolensky, A., Ben-Shushan, E., Hemo, I., Yachimovich-Cohen, N., Khaner, H., Smith, Y., Wiser, O., Gropp, M., et al. (2009) · Cell stem cell · doi:10.1016/j.stem.2009.07.002 · Cited by 486 · cited 1×
“Nicotinamide can be essential for cellular differentiation, such as for human embryonic stem cells.(256) Nicotinamide has protean endocrine effects,(257,258) can scavenge ROS, and offers cellular protection for both neuronal(253,259,260) and vascular cells.”
BackgroundCaloric restriction, SIRT1 and longevity
Cantó, C., & Auwerx, J. (2009) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2009.03.008 · Cited by 395
Mitochondria are impaired in the adipocytes of type 2 diabetic mice.
Choo, H.-J., Kim, J.-H., Kwon, O.-B., Lee, C. S., Mun, J. Y., Han, S. S., Yoon, Y.-S., Yoon, G., Choi, K.-M., & Ko, Y.-G. (2006) · Diabetologia · doi:10.1007/s00125-006-0170-2 · Cited by 365 · cited 16×
“As a result, novel and pioneering directions for drug discovery are required for safe and effective treatments for DM. Understanding the complex nature of cellular pathways and their intimate relationship is critical for the development of successful drug platforms.”
BackgroundInfluentialA local mechanism mediates NAD-dependent protection of axon degeneration
Wang, J., Zhai, Q., Chen, Y., Lin, E., Gu, W., McBurney, M. W., & He, Z. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200504028 · Cited by 352 · cited 1×
“During axonal degeneration, nicotinamide may promote protection through NAD-dependent mechanisms.(249) Nicotinamide appears to function directly at the level of mitochondrial membrane pore formation(61,250,251) to prevent the release of cytochrome c.”
BackgroundThe non‐haematopoietic biological effects of erythropoietin
Arcasoy, M. O. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07014.x · Cited by 347
Osteocyte Apoptosis Controls Activation of Intracortical Resorption in Response to Bone Fatigue
Cardoso, L., Herman, B. C., Verborgt, O., Laudier, D., Majeska, R. J., & Schaffler, M. B. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081210 · Cited by 340
Redondo, M. J., Yu, L., Hawa, M., Mackenzie, T., Pyke, D. A., Eisenbarth, G. S., & Leslie, R. D. G. (2001) · Diabetologia · doi:10.1007/s001250051626 · Cited by 322
Liang, W. S., Dunckley, T., Beach, T. G., Grover, A., Mastroeni, D., Ramsey, K., Caselli, R. J., Kukull, W. A., McKeel, D., Morris, J. C., et al. (2008) · Physiological Genomics · doi:10.1152/physiolgenomics.00242.2007 · Cited by 309
Insulin resistance and risk for stroke
Kernan, W. N., Inzucchi, S. E., Viscoli, C. M., Brass, L. M., Bravata, D. M., & Horwitz, R. I. (2002) · Neurology · doi:10.1212/wnl.59.6.809 · Cited by 280 · cited 1×
“Other variables reported in patients with type 1 DM include the presence of insulin resistance that is usually characteristic of type 2 DM and can lead to neurological and vascular disease.(16,17) Interestingly, there is a converse overlap with type 1 and type 2 DM, because almost 10% of type 2 DM patients may have el…”
BackgroundBakker, W. J., Harris, I. S., & Mak, T. W. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.10.035 · Cited by 277 · cited 1×
“On the converse side, the upregulation of FoxO proteins can indicate a positive response to chemotherapy(321,441,442) and also be an indicator and responsive agent to ischemic tissue.(443) In some scenarios, expression of FoxO proteins may suggest tissue protection and recovery, because FoxO3a activity may enhance vas…”
BackgroundDénes, Á., Ferenczi, S., Halász, J., Környei, Z., & Kovács, K. J. (2008) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2008.64 · Cited by 276
Hara, N., Yamada, K., Shibata, T., Osago, H., Hashimoto, T., & Tsuchiya, M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610357200 · Cited by 205 · cited 1×
“Nicotinamide can limit peripheral nerve injury during elevated glucose,(297) reverse type 1 DM in mice with acetyl-l-carnitine,(298) and block oxidant stress.(242,250,252,264,299) Nicotinamide affects levels of O-N-acetylglucosamin(O-GlcNAc)ylated proteins(300) and can significantly improve glucose utilization and pre…”
BackgroundDiabetes, Sarcopenia, and Frailty
Morley, J. E. (2008) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2008.03.004 · Cited by 186
OutFOXOing disease and disability: the therapeutic potential of targeting FoxO proteins
Maiese, K., Chong, Z. Z., & Shang, Y. C. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.03.002 · Cited by 182 · cited 1×
“FoxO proteins and sirtuins have been associated with cell longevity and aging as shown by early studies linking DAF-16 in Caenorhabditis elegans.(157,310,344-346) Furthermore, sirtuins are tied to cellular metabolism(343,347) and increased cell survival.”
BackgroundSelf-citationRole of nitrosative stress in the pathogenesis of diabetic vascular dysfunction
Szabo, C. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00086.x · Cited by 165 · cited 1×
“Many of the cellular pathways that lead to diabetic complications and insulin resistance have been linked to the generation of free radicals and oxidative stress.(2,3,34,35,62,64,65) In animal studies with type 1 diabetic animals, oxidative stress leads to DNA damage in renal cortical cells.”
BackgroundEvidence of islet cell autoimmunity in elderly patients with type 2 diabetes.
Pietropaolo, M., Barinas-Mitchell, E., Pietropaolo, S. L., Kuller, L. H., & Trucco, M. (2000) · Diabetes · doi:10.2337/diabetes.49.1.32 · Cited by 159
Su, F., Overholtzer, M., Besser, D., & Levine, A. J. (2002) · Genes & Development · doi:10.1101/gad.942902 · Cited by 153 · cited 1×
“Wnt has been shown in preadipocytes to increase Akt phosphorylation,(229) and the Wnt-induced secreted protein in a fibroblast cell line uses Akt to block apoptotic death.(230) Secreted Frizzled-related proteins (sFRPs), which”
BackgroundSankarapandi, S., Zweier, J. L., Mukherjee, G., Quinn, M. T., & Huso, D. L. (1998) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1998.0658 · Cited by 136
FoxO1 integrates insulin signaling to VLDL production.
Kamagate, A., & Dong, H. H. (2008) · Cell Cycle · doi:10.4161/cc.7.20.6882 · Cited by 127 · cited 1×
“Mice with a constitutively active Foxo1 transgene have increased microsomal triglyceride transfer protein and high plasma triglyceride levels.(334) Increased transcriptional activity of FoxO1, such as by the Sirt1 activator resveratrol, can decrease insulin-mediated glucose uptake and result in insulin resistance.”
BackgroundMetabolic syndrome and major depressive disorder: Co-occurrence and pathophysiologic overlap
McIntyre, R. S., Rasgon, N. L., Kemp, D. E., Nguyen, H. T., Law, C. W. Y., Taylor, V. H., Woldeyohannes, H. O., Alsuwaidan, M. T., Soczynska, J. K., Kim, B., et al. (2009) · Current Diabetes Reports · doi:10.1007/s11892-009-0010-0 · Cited by 127
Naito, A. T., Akazawa, H., Takano, H., Minamino, T., Nagai, T., Aburatani, H., & Komuro, I. (2005) · Circulation Research · doi:10.1161/01.res.0000175241.92285.f8 · Cited by 121 · cited 1×
“For example, neuronal cell differentiation requires Wnt signaling and trophic factor induction through Akt activity,(227) and differentiation of cardiomyocytes proceeds only with Akt activation.(228) Wnt has been shown in preadipocytes to increase Akt phosphorylation,(229) and the Wnt-induced secreted protein in a fib…”
BackgroundProtection of INS-1 cells from free fatty acid-induced apoptosis by targeting hOGG1 to mitochondria.
Rachek, L. I., Thornley, N. P., Grishko, V. I., LeDoux, S. P., & Wilson, G. L. (2006) · Diabetes · doi:10.2337/diabetes.55.04.06.db05-0865 · Cited by 81 · cited 2×
“Free fatty acids also can lead to ROS release, mitochondrial DNA damage, and impaired pancreatic β-cell function.(79) In patients with type 2 DM, skeletal muscle mitochondria have been described to be smaller than those in control subjects.”
BackgroundSiglec receptors and hiding plaques in Alzheimer's disease
Salminen, A., & Kaarniranta, K. (2009) · Journal of Molecular Medicine · doi:10.1007/s00109-009-0472-1 · Cited by 73
Majd, S., Zarifkar, A., Rastegar, K., & Takhshid, M. A. (2008) · Brain Research · doi:10.1016/j.brainres.2008.04.050 · Cited by 51
Unraveling the Molecular Mechanisms Behind the Metabolic Basis of Sporadic Alzheimer's Disease
Erol, A. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-1047 · Cited by 30
Cited by
Targeting disease through novel pathways of apoptosis and autophagy
Maiese, K., Chong, Z. Z., Shang, Y. C., & Wang, S. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.719499 · Cited by 150
Self-citationShedding new light on neurodegenerative diseases through the mammalian target of rapamycin
Chong, Z. Z., Shang, Y. C., Wang, S., & Maiese, K. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.08.001 · Cited by 119
Self-citationOxidant Stress and Signal Transduction in the Nervous System with the PI 3-K, Akt, and mTOR Cascade
Maiese, K., Chong, Z. Z., Wang, S., & Shang, Y. C. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131113830 · Cited by 109
“in the population throughout the world is increasing at an alarming rate that ultimately leads to metabolic disease and diabetes mellitus (DM) [66].”
BackgroundSelf-citationMammalian target of rapamycin signaling in diabetic cardiovascular disease
Chong, Z., & Maiese, K. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-45 · Cited by 95
“Type 1 insulin-dependent DM is present in approximately 10 percent of all diabetics, is increasing in adolescent minority groups, and leads to complications in the cardiovascular system [46,47].”
BackgroundSelf-citation
Metadata
- Authors
- Maiese, K., Chong, Z. Z., Shang, Y. C., & Hou, J.
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2011-02
- Volume
- 51
- Issue
- 2
- Pages
- 128-152
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- OpenAlex
- W2075183909
- Cited by
- 46
- References
- 41
- FWCI
- 1.85
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.